SecBot SecBot
SECBOTREPLAY Home › Report › REGN

REGN · Benchmark double-upgraded REGN from Hold to Buy on July 7, 2026, but…

REGENERON PHARMACEUTICALS, INC. · ANALYST-UPGRADE filed Jul 7, 2026 at 06:36 ET

At the news

MIXEDIMPACT 2/10

ANALYST-UPGRADE filed Jul 7, 2026 at 06:36 ET

Benchmark double-upgraded REGN from Hold to Buy on July 7, 2026, but set a price target of $185, implying a 71.5% downside from the current $649.81, an extreme divergence from the consensus mean of $833.31. The firm's 54% accuracy on 1,703 calls is average, and its average return of 6% is in line with peers. Consensus remains heavily bullish: 71% Buy (27 of 38 analysts), 29% Hold, 0% Sell. The mean target of $833.31 offers 28.2% upside, with a high of $1,000 and low of $641. Benchmark's $185 target sits far below the lowest Street estimate. 30-day analyst momentum shows 1 upgrade and 0 downgrades, while EPS revisions are net positive for the next quarter and current year. Insider sales by Arthur F Ryan (~$51K on May 1) are small and non-informative; a congressional buy by Ro Khanna adds a minor bullish signal. The double upgrade is a strong directional call, but the contradictory price target creates confusion, traders should treat this as an outlier until clarified.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access